Shots:
InnoRNA will receive an up front & and additional fees upon achievement of development, regulatory & commercial milestones along with royalties for the mRNA-LNP research collaboration programs where BeiGene will obtain an exclusive development & commercialization rights globally
BeiGene will gain a non-exclusive license for the LNP technology platform for which InnoRNA will additionally receive upfront & is eligible to receive milestones to support internal discovery efforts
The collaboration b/w InnoRNA & BeiGene will advance & support their research in mRNA therapies along with securing critical, proprietary delivery tools
Ref: Bussinesswire | Image: BeiGene
